{"bill": {"#text": "\n\t", "form": {"current-chamber": {"#tail": "\n\t\t", "#text": "IN THE SENATE OF THE UNITED STATES"}, "#text": "\n\t\t", "congress": {"#tail": "\n\t\t", "#text": "113th CONGRESS"}, "#tail": "\n\t", "legis-num": {"#tail": "\n\t\t", "#text": "S. 2996"}, "official-title": {"#tail": "\n\t", "#text": "To create a limited population pathway for approval of certain antibacterial drugs."}, "session": {"#tail": "\n\t\t", "#text": "2d Session"}, "distribution-code": {"#tail": "\n\t\t", "@display": "yes", "#text": "II"}, "action": {"action-date": {"#tail": "\n\t\t\t", "@date": "20141210", "#text": "December 10, 2014"}, "#tail": "\n\t\t", "action-desc": {"#tail": "\n\t\t", "#text": "\n        ", "committee-name": {"#tail": "\n      ", "@committee-id": "SSHR00", "#text": "Committee on Health, Education, Labor, and Pensions"}, "sponsor": {"#tail": " (for himself and ", "#text": "Mr. Bennet", "@name-id": "S330"}, "cosponsor": {"#tail": ") introduced the following bill; which was read twice and referred to the ", "#text": "Mr. Hatch", "@name-id": "S118"}}, "#text": "\n\t\t\t"}, "legis-type": {"#tail": "\n\t\t", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-Senate", "@public-private": "public", "legis-body": {"#tail": "\n", "section": [{"@section-type": "section-one", "#tail": "\n    ", "text": {"#tail": "\n\t\t", "#text": "This Act may be cited as\n\t\t\t the ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "\n      ", "quote": [{"short-title": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "act", "#text": "Promise for Antibiotics and Therapeutics for Health Act", "@value": "Promise for Antibiotics and Therapeutics for Health Act", "@proposed": "true"}, "#text": "\n              "}, "#tail": " or the ", "#text": "\n          "}, {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "act", "#text": "PATH Act", "@value": "PATH Act", "@proposed": "true"}, "#text": "\n            "}], "@entity-type": "law-citation", "#text": "\n          "}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n\t\t\t", "#text": "1."}, "header": {"#tail": "\n\t\t\t", "#text": "Short\n\t\t\t title"}, "#text": "\n\t\t\t", "@id": "S1"}, {"#tail": "\n  ", "text": {"#tail": "\n\t\t\t", "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 506\n\t\t\t of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:506"}, "@entity-type": "law-citation", "#text": "\n          ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n        ", "@entity-type": "uscode", "#text": "21 U.S.C. 356", "@value": "usc/21/356"}, "@parsable-cite": "usc/21/356", "#text": "\n          ", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n\t\t\t", "#text": "2."}, "header": {"#tail": "\n\t\t\t", "#text": "Limited\n\t\t\t population pathway for antibacterial drugs"}, "paragraph": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "by transferring\n\t\t\t subsection (e) so that it appears before subsection (f); and"}, "enum": {"#tail": "\n\t\t\t\t", "#text": "(1)"}, "@id": "idD3C0C8FD2520427093E78BAD7F5C5288", "#text": "\n\t\t\t\t"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t\t", "#text": "by adding at the\n\t\t\t end the following:"}, "enum": {"#tail": "\n\t\t\t\t", "#text": "(2)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n\t\t\t", "subsection": {"#tail": "\n          ", "enum": {"#tail": "\n\t\t\t\t\t\t", "#text": "(g)"}, "header": {"#tail": "\n\t\t\t\t\t\t", "#text": "Limited\n\t\t\t\tpopulation pathway for antibacterial drugs"}, "paragraph": [{"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall establish a program under which the\n\t\t\t\t", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " may, at the request of a sponsor, approve an\n\t\t\t antibacterial drug, alone\n\t\t\t or in combination with one or\n\t\t\t\tmore drugs, as a limited population antibacterial drug, upon a\n\t\t\t determination that\n\t\t\t\tsuch drug is intended to treat a serious or life-threatening\n\t\t\t disease, condition,\n\t\t\t or infection\n\t\t\t\tand address an unmet medical need for\n\t\t\t such disease,\n\t\t\t\tcondition, or infection within an identifiable limited population.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "The "}, "enum": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "(1)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "In\n\t\t\t\tgeneral"}, "#text": "\n\t\t\t\t\t\t\t", "@id": "id112971D6C8F44F849B935A614E80DD80"}, {"#tail": "\n            ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " determines to be eligible for approval as a\n\t\t\t limited\n\t\t\t\tpopulation antibacterial drug shall be required to demonstrate the\n\t\t\t safety and\n\t\t\t\teffectiveness of such drug, as required under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " or\n\t\t\t ", "@entity-type": "act", "#text": "section 505(d)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:d"}, {"#tail": ", for the intended use of the drug.\n\t\t\t The ", "@entity-type": "act", "#text": "section 351(a)\n\t\t\t\tof the Public Health Service Act", "@value": "Public Health Service Act/s:351/ss:a"}, {"#tail": " shall determine the safety and\n\t\t\t effectiveness of an antibacterial drug under the limited population\n\t\t\t pathway for antibacterial drugs in accordance\n\t\t\t with subparagraph (B). An antibacterial drug shall be eligible for\n\t\t\t approval under the limited population pathway only upon the request of the\n\t\t\t sponsor.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "The sponsor of an antibacterial drug that the "}, "enum": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "(A)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "In general"}, "#text": "\n\t\t\t\t\t\t\t\t", "@id": "idA8FC6A92523A42CDB114416CC716956F"}, {"#tail": "\n            ", "clause": [{"#tail": "\n                ", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " determination of safety and effectiveness  of a limited population antibacterial\n\t\t\t drug shall reflect the benefit-risk profile of the drug in the intended\n\t\t\t limited\n\t\t\t population, taking into account the severity, rarity, or prevalence of the\n\t\t\t infection the drug is intended to treat and the availability or lack of\n\t\t\t alternative treatment for such infection. Approval of a drug under the\n\t\t\t limited population\n\t\t\t antibacterial drug pathway shall not be denied due to a lack of\n\t\t\t evidence to fully establish a favorable benefit-risk profile in a\n\t\t\t population that is broader than the intended limited population.", "@entity-type": "federal-body", "#text": "Secretary\u2019s", "@entity-id": "7500"}, "#text": "The "}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "header": {"#tail": "\n                  ", "#text": "Benefit-risk profile"}, "#text": "\n                  ", "@id": "id57C35FA77824499D9D20671BAED53FAD"}, {"#tail": "\n              ", "subclause": [{"#tail": "\n                  ", "text": {"#tail": "\n                  ", "#text": "shall rely on sufficient  evidence, which may include traditional endpoints, alternate endpoints,\n\t\t\t or a combination of traditional and alternate endpoints, and, as\n\t\t\t appropriate, small clinical data sets; and"}, "enum": {"#tail": "\n                    ", "#text": "(I)"}, "@id": "idCB7F9BD7D9CC4BFA94D352595ECAB923", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n                  ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " determines appropriate.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "may rely on supplemental data, including preclinical evidence, pharmacologic or pathophysiologic\n\t\t\t evidence, nonclinical susceptibility, pharmacokinetic data, and other such\n\t\t\t confirmatory evidence as the "}, "enum": {"#tail": "\n                    ", "#text": "(II)"}, "@id": "id25777F68FCC34561B3368BD8C2C1A720", "#text": "\n                    "}], "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "header": {"#tail": "\n                  ", "#text": "Types of evidence"}, "text": {"#tail": "\n                  ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "In determining whether to approve a drug under the limited population pathway, the "}, "#text": "\n                  ", "@id": "id2010075A76E1481BBFF5D2DC66764F7A"}], "enum": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "(B)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Considerations"}, "#text": "\n\t\t\t\t\t\t\t\t", "@id": "idBE47FDBAD8E84FF0B482A9D72AD47F7C"}], "enum": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "(2)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Limited population pathway"}, "#text": "\n\t\t\t\t\t\t\t", "@id": "id104A34188ADE4FAF92B22A4A11D3AB52"}, {"#tail": "\n            ", "@id": "id7D230F4E772C40A5BD8368D8DDE023A8", "enum": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "(3)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Requirements"}, "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall require\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "With\n\t\t\t\trespect to a drug approved through the limited population pathway,\n\t\t\t the\n\t\t\t\t"}, "#text": "\n\t\t\t\t\t\t\t", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "the labeling of\n\t\t\t\tsuch antibacterial drug, such as through a logo or other means, to\n\t\t\t indicate that\n\t\t\t the drug has\n\t\t\t\tbeen approved for use only in a limited population and that the\n\t\t\t safety and\n\t\t\t\tefficacy of the drug has been demonstrated only with respect to\n\t\t\t such limited\n\t\t\t\tpopulation; and"}, "enum": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "(A)"}, "@id": "id36EA880BF3964FFCB73A4CC85C66106E", "#text": "\n\t\t\t\t\t\t\t\t"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "the sponsor to\n\t\t\t\tsubmit copies of all promotional materials related to the limited\n\t\t\t population antibacterial drug, at least\n\t\t\t 30 days\n\t\t\t\tprior to dissemination of the materials."}, "enum": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "(B)"}, "@id": "id663FC886B96E401EB67DA582C482507C", "#text": "\n\t\t\t\t\t\t\t\t"}]}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and ", "@entity-type": "act", "#text": "sections 505E", "@value": "Federal Food, Drug, and Cosmetic Act/s:505E"}, {"#tail": ".", "@entity-type": "act", "#text": "524", "@value": "Federal Food, Drug, and Cosmetic Act/s:524"}], "#text": "A sponsor of a drug that seeks approval of a drug\n\t\t\t\tthrough the limited population pathway for antibacterial drugs may\n\t\t\t also seek approval of\n\t\t\t such drug under subsections (a), (b), and (c), and\n\t\t\t\t"}, "enum": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "(4)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Other\n\t\t\t\tprograms"}, "#text": "\n\t\t\t\t\t\t\t", "@id": "id1E68F35C87E2470D987E8F9E548BAA59"}, {"#tail": "\n            ", "text": {"short-title": {"#tail": ", the ", "#text": "Promise for Antibiotics and Therapeutics for Health Act"}, "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall issue draft guidance describing criteria, processes, and other general\n\t\t\t considerations  for\n\t\t\t demonstrating the safety and effectiveness of limited\n\t\t\t\tpopulation antibacterial drugs and how the pathway can be expanded\n\t\t\t to other therapeutic areas in addition to antibacterial infections. The\n\t\t\t ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " may approve antibacterial drugs\n\t\t\t through such limited population pathway prior to issuing guidance under\n\t\t\t this paragraph.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#tail": "\n\t\t\t\t\t\t", "#text": "Not later than 18 months after the\n\t\t\t\tdate of enactment of the "}, "enum": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "(5)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Guidance"}, "#text": "\n\t\t\t\t\t\t\t", "@id": "idC5A022E272824DE885F816239B8FC344"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", in consultation with the\n\t\t\t\tCommissioner and other relevant heads of agencies, shall conduct\n\t\t\t postapproval monitoring\n\t\t\t\tprograms to study how antibacterial drugs approved through the\n\t\t\t pathway under this subsection\n\t\t\t\tare used and to monitor changes in bacterial resistance to drugs,\n\t\t\t including drugs approved under this pathway.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "The "}, "enum": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "(6)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Postapproval\n\t\t\t\tmonitoring programs for antibacterial drugs"}, "#text": "\n\t\t\t\t\t\t\t", "@id": "idA1839F77A5BD4A76B346D41325FE99B0"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall provide prompt advice to the sponsor of a drug\n\t\t\t for which the sponsor seeks approval through the\n\t\t\t\tlimited population pathway for antibacterial drugs to enable\n\t\t\t the sponsor\n\t\t\t\tto plan a development program to obtain the necessary data for\n\t\t\t\tapproval of such drug through the limited population\n\t\t\t\tpathway for antibacterial drugs and to conduct any additional\n\t\t\t studies that would be\n\t\t\t\trequired to gain approval of such drug for use in a broader\n\t\t\t population.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "The\n\t\t\t\t"}, "enum": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "(7)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Advice"}, "#text": "\n\t\t\t\t\t\t\t", "@id": "id67A45DB4E3504504B84A5A9FA82B59E3"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " approves a broader\n\t\t\t indication for such drug for\n\t\t\t\twhich the sponsor applies under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " or ", "@entity-type": "act", "#text": "section 505(b)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:b"}, {"#tail": ", the\n\t\t\t ", "@entity-type": "act", "#text": "section 351 of\n\t\t\t the Public\n\t\t\t\tHealth Service Act", "@value": "Public Health Service Act/s:351"}, {"#tail": " may\n\t\t\t\tremove any postmarketing conditions, including requirements with\n\t\t\t respect to labeling and review of promotional materials under paragraph\n\t\t\t (3) and postapproval monitoring under paragraph (6), applicable to the\n\t\t\t approval of\n\t\t\t the drug through the\n\t\t\t\tlimited population pathway\n\t\t\t\tfor antibacterial drugs.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "If, after approval of a drug through the limited population pathway for antibacterial drugs, the\n\t\t\t "}, "enum": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "(8)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Termination of limitations"}, "#text": "\n\t\t\t\t\t\t\t", "@id": "id0BA289D6C5D14D7CAF89BC05D0F0E9D8"}, {"#tail": "\n            ", "subparagraph": [{"#tail": "\n              ", "text": {"short-title": {"#tail": ".", "#text": "Promise for Antibiotics and Therapeutics for Health Act"}, "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", or to modify or limit the authority of the\n\t\t\t ", "@entity-type": "act", "#text": "Public Health Service\n\t\t\t Act", "@value": "Public Health Service Act"}, {"#tail": " to approve or monitor drugs pursuant to this Act or the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " as authorized prior to the date of enactment of the ", "@entity-type": "act", "#text": "Public\n\t\t\t Health\n\t\t\t Service Act", "@value": "Public Health Service Act"}], "#tail": "\n              ", "#text": "Nothing in this subsection shall be construed to alter the standards of evidence applicable to the\n\t\t\t review and approval of a drug under this Act or the "}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "header": {"#tail": "\n                ", "#text": "Standards of evidence and authority of Secretary"}, "#text": "\n                ", "@id": "idF5532A05447B4E48B79433B0A5F4C677"}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "#text": "Nothing in this subsection shall be construed to restrict  the\tprescribing  of  antibiotics  or \n\t\t\t other\tproducts, including drugs approved under the limited population\n\t\t\t pathway, by  health  care  professionals,  or\tto  limit  the \n\t\t\t practice  of health care."}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "header": {"#tail": "\n                ", "#text": "Prescribing authority"}, "#text": "\n                ", "@id": "id909F727B46514604B4F4EA83F4D65583"}], "enum": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "(9)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Rules of construction"}, "#text": "\n\t\t\t\t\t\t\t", "@id": "id3F56A69538564C6589A1C7A2B11DCAF3"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " delivers a report to ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " prior to\n\t\t\t that date explaining why such pathway should not be used for other\n\t\t\t therapeutic areas in addition to antibacterial infections.", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}], "#text": "Beginning on October 1, 2016, the limited population pathway for antibiotic drugs may be expanded\n\t\t\t to apply to approval of other drugs intended to treat a serious or\n\t\t\t life-threatening illness. The\n\t\t\t approval of such drugs shall be\n\t\t\t subject to the considerations and requirements described in this\n\t\t\t subsection, unless the "}, "enum": {"#tail": "\n              ", "#text": "(10)"}, "header": {"#tail": "\n              ", "#text": "Expansion of pathway"}, "#text": "\n              ", "@id": "id62A839AB70E0455F8CC32B92EA427E5F"}], "#text": "\n\t\t\t\t\t\t", "@id": "id83DEA048E6C643C6BBB9CDA7C071BC36"}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t", "@id": "id2102135234C04AD8973FE2CA0ED5AE56"}, "#text": "\n\t\t\t\t", "@id": "id3663193622894CB99899F19499451F93"}], "#text": "\n\t\t\t", "@id": "id8E6CD1E6467740F4BCF6751C705335CF"}], "#text": "\n\t\t"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2014-12-10"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 S2996 IS: Promise for Antibiotics and Therapeutics for Health Act"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. Senate"}, "#text": "\n"}, "#text": "\n"}}}